139 completed. 139 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 139 | Completed 139 |
Follow Psoriasis: new trials by email Literature Review of Psoriasis trials Research Report on Psoriasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Psoriasis With Depression and/or Anxiety With Methotrexate vs Combined Methotrexate and Antidepressant Combination of methotrexate and escitalopram in treatment of psoriasis patients with depression and/or anxiety, Methotrexate - Depression, Anxiety | Phase 4 | Completed | Cairo University | 40 | 2026-02-01 | 2026-10-05 |
| A Study to Assess Efficacy and Tolerability of Topical Skincare Products on Psoriasis Patients Cetaphil - Plaque Psoriasis, Psoriasis | Phase 4 | Completed | Galderma R&D | 46 | 2024-04-08 | 2026-06-09 |
| A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares Spesolimab - Generalized Pustular Psoriasis | Phase 4 | Completed | LEO Pharma | 42 | 2023-10-22 | 2026-10-26 |
| Effect of Metformin on Carotid Atherosclerosis for Non-diabetic Patients With PsA (CAMPA Study) Metformin - PsA (Psoriatic Arthritis) | Phase 4 | Completed | Chinese University of Hong Kong | 24 | 2023-08-30 | 2025-11-24 |
| Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis Risankizumab, Placebo for Risankizumab - Genital Psoriasis, Scalp Psoriasis | Phase 4 | Completed | AbbVie | 214 | 2023-08-10 | 2026-02-24 |
| A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India Ixekizumab - Plaque Psoriasis, Psoriatic Arthritis | Phase 4 | Completed | Eli Lilly and Company | 250 | 2023-06-27 | 2025-08-22 |
| Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus Semaglutide - Psoriasis Vulgaris, Diabetes Type 2 | Phase 4 | Completed | University of Banja Luka | 30 | 2023-05-03 | 2024-07-01 |
| A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region VTAMA (tapinarof) cream, 1% - Psoriasis | Phase 4 | Completed | Organon and Co | 31 | 2023-03-13 | 2025-06-12 |
| Vtama in Psoriasis Patients Being Treated With Biologics. Tapinarof - Psoriasis | Phase 4 | Completed | Psoriasis Treatment Center of Central New Jersey | 30 | 2023-02-27 | 2023-10-27 |
| A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting Deucravacitinib, Placebo - Psoriasis | Phase 4 | Completed | Bristol-Myers Squibb | 180 | 2023-01-31 | 2026-06-03 |
| A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis VTAMA® (tapinarof) Cream 1% - Psoriasis | Phase 4 | Completed | Organon and Co | 34 | 2022-12-27 | 2025-06-12 |
| Combination of Sotyktu and Enstilar for Plaque Psoriasis Enstilar, Deucravacitinib - Psoriasis | Phase 4 | Completed | Psoriasis Treatment Center of Central New Jersey | 30 | 2022-12-06 | 2024-03-25 |
| Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis Deucravacitinib, Placebo - Psoriasis | Phase 4 | Completed | Bristol-Myers Squibb | 154 | 2022-10-06 | 2025-10-28 |
| Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis Humira (Adalimumab), SB5 (Adalimumab Biosimilar) - Plaque Psoriasis | Phase 4 | Completed | Samsung Bioepis Co., Ltd. | 371 | 2022-08-04 | 2023-05-25 |
| Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases tozinameran - Bullous Dermatoses, Psoriasis | Phase 4 | Completed | Mahidol University | 109 | 2022-06-15 | 2024-03-25 |
| Effects of Tildrakizumab on Epigenetic Age TILDRAKIZUMAB - Psoriasis, Aging | Phase 4 | Completed | Carlos Wambier | 30 | 2022-04-08 | 2024-07-18 |
| Efficacy and Safety of Infliximab Biosimilar Remsima in Psoriasis Remsima - Psoriasis | Phase 4 | Completed | Ghurki Trust and Teaching Hospital | 51 | 2022-03-10 | 2023-09-21 |
| Efficacy and Safety of Apremilast in Psoriasis Apremilast 30mg - Psoriasis | Phase 4 | Completed | Ghurki Trust and Teaching Hospital | 30 | 2022-03-06 | 2023-09-13 |
| Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV) Secukinumab Auto-Injector - Psoriasis | Phase 4 | Completed | University of Pennsylvania | 16 | 2022-02-07 | 2026-10-30 |
| COVID-19 VaccinE Response in Rheumatology Patients Upadacitinib, Abatacept, Secukinumab - Rheumatoid Arthritis, Psoriatic Arthritis | Phase 4 | Completed | Jeffrey Curtis | 841 | 2021-11-15 | 2025-05-02 |
Showing 20 of 139. Sign in to see all of them.
Arthritis, Psoriatic (24) · Skin Diseases (7) · Arthritis (5) · Cardiovascular Diseases (5) · Dermatitis, Atopic (4) · Arthritis, Rheumatoid (3) · Obesity (3) · Coronary Artery Disease (2) · Crohn Disease (2) · Joint Diseases (2) · Lymphoma, Follicular (2) · Plaque, Amyloid (2) · Spondylarthritis (2) · Spondylitis, Ankylosing (2)
Skin and Connective Tissue Diseases (139) · Skin Diseases, Papulosquamous (138) · Skin Diseases (132) · Musculoskeletal Diseases (27) · Joint Diseases (25) · Bone Diseases (24) · Spinal Diseases (24) · Spondylarthropathies (23) · Spondylitis (23) · Arthritis (22) · Spondylarthritis (22) · Immune System Diseases (8) · Pathological Conditions, Signs and Symptoms (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4)
Etanercept (21) · Adalimumab (15) · secukinumab (12) · Methotrexate (11) · apremilast (8) · Infliximab (5) · efalizumab (5) · ixekizumab (5) · Acitretin (4) · Clobetasol (4) · Ustekinumab (4) · betamethasone dipropionate, calcipotriol drug combination (4) · risankizumab (4) · Alefacept (3) · Sodium Chloride (3)
Amgen (8) · Psoriasis Treatment Center of Central New Jersey (6) · Innovaderm Research Inc. (5) · Novartis Pharmaceuticals (5) · Pfizer (5) · University Hospital, Ghent (5) · University of Pennsylvania (5) · Genentech, Inc. (4) · University of California, San Francisco (4) · Wyeth is now a wholly owned subsidiary of Pfizer (4) · AbbVie (3) · Chinese University of Hong Kong (3) · Eli Lilly and Company (3) · Icahn School of Medicine at Mount Sinai (3) · Merck KGaA, Darmstadt, Germany (3)
United States (59) · Germany (17) · Belgium (16) · Canada (16) · United Kingdom (14) · Spain (13) · Italy (12) · Denmark (11) · France (10) · Poland (9) · Hungary (8) · Netherlands (8) · Austria (7) · Switzerland (7) · Finland (6)
Robert Bissonnette, MD (4) · Ivor Caro, M.D. (3) · Jo Lambert, Prof. (3) · Boni Elewski, MD (2) · Dr. Sumera Hanif (2) · Prof. Dr. Haroon Nabi (2)
PMID 25913550, PMID 29776990, PMID 42694939, PMID 17092858, PMID 17373192, PMID 17500381, PMID 17853307, PMID 18047523, PMID 18380206, PMID 18856162, PMID 19740906, PMID 20098509, PMID 20098510, PMID 20124563, PMID 20399899, PMID 20428228, PMID 21173304, PMID 21455550, PMID 21551511, PMID 21797805, PMID 22035157, PMID 22127697, PMID 22751454, PMID 23204039, PMID 23468464, PMID 23981683, PMID 24120032, PMID 24369412, PMID 24682319, PMID 24861696, PMID 25087839, PMID 25231176, PMID 25434285, PMID 25535650, PMID 25946554, PMID 25994179, PMID 26641955, PMID 27455955, PMID 27462386, PMID 28286061, PMID 28482858, PMID 28502609, PMID 29295985, PMID 29654699, PMID 30323006, PMID 30762274, PMID 31163241, PMID 32049319, PMID 32088207, PMID 32403379
2016 (4), 2018 (3), 2005 (1), 2008 (1), 2014 (1), 2015 (1), 2019 (1), 2023 (1), K23AR080043 (1)